BioCentury
ARTICLE | Clinical News

Axalimogene filolisbac regulatory update

July 25, 2016 7:00 AM UTC

EMA classified Advaxis’ axalimogene filolisbac as an advanced therapy medicinal product (ATMP). The live Listeria monocytogenes-based immunotherapy expressing E7 transforming protein ( Human papilloma...